SCNIScinai Immunotherapeutics Ltd.

Nasdaq biondvax.com


$ 0.45 $ 0.04 (9.02 %)    

Monday, 29-Apr-2024 09:38:11 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 0.47
$ 0.45
$ 0.00 x 0
$ 0.47 x 100
$ 0.45 - $ 0.45
$ 0.43 - $ 2.27
14,483
na
15.44M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2023 03-31-2023 10-Q
2 04-17-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 scinai-immunotherapeutics-cdmo-unit-and-ayana-pharma-signed-a-five-year-master-service-agreement-to-provide-drug-development-and-cgmp-manufacturing-services

Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assu...

 scinai-reports-preclinical-trial-results-of-its-antiil17-vhh-antibody-intends-to-conduct-an-in-vivo-proof-of-concept-animal-study-in-early-2024

The statistically significant results demonstrated the potential for Scinai's anti-IL-17 NanoAbs to noticeably improve psor...

 scinai-immunotherapeutics-ltd-announces-the-publication-following-peer-review-of-an-article-titled-nanobodies-to-multiple-spike-variants-and-inhalation-of-nanobody-containing-aerosols-neutralize-sars-cov-2-in-cell-culture-and-hamsters

Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, address...

 scinai-immunotherapeutics-provides-update-regarding-nasdaq-compliance

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company focused on developing, manufacturing, and commerciali...

 european-investment-bank-considering-extending-maturity-of-its-financial-facility-contract-with-scinai-immunotherapeutics-in-light-of-scinais-recent-strategic-pivot

Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the ...

 scinai-immunotherapeutics-q3-eps-002-down-from-006-yoy

Scinai Immunotherapeutics (NASDAQ:SCNI) reported quarterly losses of $(0.02) per share. This is a 133.33 percent decrease over ...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION